The report highlights Biogen's commitment to improving patient outcomes, with a focus on social and environmental responsibility. The company celebrated its 40th anniversary in 2018, and highlights include: approval of SPINRAZA for SMA, 3 anti-TNF biosimilars offered in Europe, and 11 clinical programs added or advanced. In addition, Biogen continued its commitment to carbon neutrality, with a 76% reduction in operational carbon intensity since 2006 and is working to reduce emissions by 35% by 2030. The report also highlights Biogen's commitment to diverse and inclusive workplaces, with 51% of their workforce being women and 22% being ethnic or racial minorities in U.S. management. Biogen emphasizes their dedication to science-based environmental practices and green chemistry. In addition, Biogen launched the STAR initiative, a $10 million commitment over four years to support STEM education in Cambridge and Somerville, MA. Lastly, the report details Biogen's community engagement, including their Care Deeply Day, where employees participate in volunteer projects around the world, and the Biogen Foundation's commitment to supporting access to science education and essential human services in their communities.
